CEO Executive AssistantThe commercial launch of a pharmaceutical product is one of the most capital-intensive and strategically complex events a company can execute. For a pharma CEO, the instinct to stay closely involved in commercial planning, sales strategy, and marketing decisions is understandable. The stakes are enormous, the timelines are compressed, and the margin for error is narrow.
But a CEO who is managing commercial operations is not managing the company. The two roles are fundamentally different, and conflating them creates predictable problems: slow decision cycles, a commercial organization that waits for executive direction rather than acting, and a CEO who is too deep in the tactics to see the strategic landscape clearly.
Building a structured delegation system for the commercial function frees the CEO to focus on what they alone can do while giving the commercial organization the authority it needs to execute.
Understanding the Commercial Function in Pharma
Pharmaceutical commercial organizations are large, complex, and span multiple distinct functions. An effective delegation system must account for each of them:
Sales and field force: The primary customer-facing function. Includes field sales representatives, regional managers, national sales directors, and sales operations. Responsible for HCP engagement, formulary pull-through, and market share execution.
Marketing: Brand marketing (specialty and primary care), medical affairs coordination, promotional materials development, digital marketing, market research, and launch planning.
Managed markets and market access: Payer strategy, formulary positioning, rebate negotiations, specialty pharmacy relationships, hub services, and patient support programs.
Commercial analytics and operations: Sales force sizing and design, territory optimization, CRM management, incentive compensation, and commercial data infrastructure.
Medical affairs commercial interface: Medical science liaisons, medical information, and scientific communication. Sits at the intersection of medical and commercial.
Each of these functions has a distinct rhythm, distinct accountabilities, and distinct decision types. A single authority framework will not cover all of them; the delegation system needs to map each one.
The Commercial Leadership Structure
The CEO’s delegation system begins with a clear commercial leadership structure. In most pharma companies, this centers on:
Chief Commercial Officer or VP of Commercial: Owns the integrated commercial strategy across all functions. Accountable to the CEO for commercial performance. This is the primary delegation recipient for commercial authority.
VP of Sales: Owns field force execution, regional performance, and HCP engagement strategy. Reports to the CCO.
VP of Marketing: Owns brand strategy, promotional execution, and launch readiness. Reports to the CCO.
VP of Market Access: Owns payer strategy, formulary positioning, and patient access infrastructure. Reports to the CCO.
The CEO’s relationship to commercial operations should primarily run through the CCO. Direct CEO relationships with the VP-level commercial leaders are appropriate for performance reviews and strategic input, but day-to-day operational decisions should route through the CCO.
Defining CEO-Level Commercial Decisions
Not all commercial decisions require CEO involvement. One of the most important things a CEO can do is be explicit about which decisions they must make and which ones the commercial team should make without them.
CEO-level decisions:
- Commercial launch go/no-go decisions and launch timing
- Major pricing strategy decisions, including launch price and significant pricing adjustments
- Commercial organization structure changes above the VP level
- Major payer contract negotiations above a defined contract value threshold
- Decisions about entering or exiting a therapeutic area commercially
- Commercial co-promotion or co-marketing agreements
- Significant changes to commercial investment levels (budget allocation above a defined threshold)
CCO decisions (CEO informed, not approving):
- Sales force size and structure adjustments within approved headcount
- Regional sales leadership hiring and performance management
- Brand plan approval within approved budgets
- Formulary positioning strategy within approved pricing parameters
- Agency of record selection and management
- Commercial technology platform decisions within approved budgets
VP-level decisions (CCO informed):
- Regional sales operations decisions
- Marketing campaign execution within approved brand plans
- Market access tactical negotiations within approved parameters
- Sales incentive plan design within approved budget ranges
- Individual territory and district management decisions
Executed within SOPs:
- Field rep call planning and HCP targeting within approved guidelines
- Promotional material deployment following MLR approval
- CRM data maintenance and reporting
- Routine payer communications following approved messaging
Sales Organization Delegation
The sales organization is the largest commercial cost center and the most execution-dependent function. CEOs who stay too close to sales management create significant organizational dysfunction: field leaders learn to wait for top-down direction rather than developing judgment.
The CEO’s appropriate engagement with the sales organization focuses on:
Strategy: The CEO sets the strategic context for commercial execution. What is the market share goal? What is the competitive positioning? What patient segments are the priority? These questions belong to the CEO. How the sales force executes against them belongs to the VP of Sales.
Performance accountability: The CEO holds the CCO accountable for commercial performance. The CEO should see commercial performance dashboards at a portfolio level, not field-level sales data. If the CEO is reviewing territory-level performance reports, the organization has a delegation problem.
Leadership development: The CEO should have direct relationships with the VP of Sales and other senior commercial leaders, including direct input on their development and succession planning.
Culture: The CEO sets the tone for how the commercial organization operates, including its ethics culture. This is done through communication, recognition, and accountability, not through managing sales calls.
The CEO should not be: approving individual call plans, reviewing field ride-along reports, participating in district manager calls, or managing CRM compliance initiatives. Those belong entirely to the sales management chain.
Marketing Delegation: Brand Authority and Approval Workflows
Marketing in pharma operates under a regulatory approval process (the Medical-Legal-Regulatory review) that creates built-in approval structure. CEOs sometimes confuse their role in MLR with broader marketing authority. They are different.
The CEO’s role in MLR is generally not a standing one. MLR review involves medical, legal, and regulatory reviewers. The CEO may review final brand campaign elements for major launches, but should not be a standing MLR reviewer for routine promotional materials.
Beyond MLR, the marketing delegation structure should define:
Brand plan ownership: The VP of Marketing owns the annual brand plan. The CEO approves the strategic framework (positioning, investment levels, major launch elements) but does not review the tactical plan in detail.
Campaign development: Marketing owns creative development and agency management. The CEO may provide input on major campaign concepts but should not be in the day-to-day creative review process.
Digital marketing: Owned entirely by marketing within approved brand guidelines. Social media, HCP-targeted digital, and patient-facing digital are executed by marketing without CEO involvement in individual placements.
Market research: Marketing owns the market research program. The CEO should see major research findings that affect strategic decisions; routine tracking data stays with marketing.
Managed Markets: Authority on Payer Strategy
Market access decisions have significant P&L implications. CEOs are appropriately involved in the strategic dimensions: launch pricing, payer strategy positioning, and major formulary negotiations.
Below the strategic level, the VP of Market Access should have substantial authority to execute the payer strategy without CEO involvement in individual negotiations. This requires:
Clear pricing guardrails: The CEO approves the pricing strategy and defines the acceptable range for formulary negotiations. The VP of Market Access executes within those guardrails without coming back for CEO approval on individual payer contracts, unless a contract falls outside the defined parameters.
Escalation triggers: Define the contract value, formulary tier, or rebate level that triggers CEO involvement. Contracts above that threshold come to the CEO; contracts below it are handled by the VP of Market Access.
Patient access infrastructure: Hub services, specialty pharmacy relationships, and patient support program design are owned by the VP of Market Access within approved budgets. The CEO should see program performance metrics, not operational details.
Commercial Analytics as the CEO’s Visibility Tool
A CEO who has delegated commercial authority needs a strong commercial analytics function to maintain visibility without operational involvement.
The CEO’s commercial information package should include:
Weekly: A one-page commercial performance snapshot. Total prescriptions by product, market share trends, managed care coverage summary, any significant competitive developments.
Monthly: A CCO briefing covering brand performance against plan, any significant payer developments, sales force performance summary, and any decisions or CEO input needed.
Quarterly: A full commercial business review. Performance against annual plan, market dynamics, competitive landscape updates, and forward-looking forecast adjustments.
Ad hoc: Any significant competitive event, a major payer formulary decision, safety or regulatory development affecting commercial execution, or a major variance from plan that triggers a strategic response.
This information architecture keeps the CEO strategically informed without pulling them into operational detail. If the CEO needs to request data below the portfolio level to understand what is happening, it is a signal that the commercial analytics function needs improvement, not that the CEO needs deeper operational involvement.
Connecting Commercial Delegation to the Full Organization
A pharma CEO’s commercial delegation system does not operate in isolation. It connects to the clinical and regulatory functions that determine what products are available to commercialize, and to the financial planning function that allocates commercial investment.
For CEOs building the full delegation architecture, pharma delegation strategies covers the cross-functional coordination model, and pharma regulatory delegation addresses the authority map for the regulatory function that commercial planning depends on.
McKinsey’s research on commercial excellence in biopharmaceuticals documents how leading companies separate strategic commercial leadership from operational execution, with significant implications for how CEOs structure their involvement in the commercial function.
The Common Failure: Re-engaging During Launches
The most common failure mode in pharma commercial delegation is the CEO who has generally delegated commercial operations but re-engages operationally during a product launch. The logic is understandable: launches are high-stakes, time-limited events where execution quality matters enormously. But CEO re-engagement during a launch creates exactly the organizational dysfunction the delegation system was designed to prevent.
When the CEO starts reviewing individual call plans, attending weekly launch readiness calls, and approving tactical marketing decisions during a launch, the commercial organization learns two things: their authority is contingent rather than real, and the CEO does not trust them to execute. Both lessons persist well after the launch is over.
The right model: the CEO is deeply involved in launch strategy before the launch begins. Positioning, pricing, investment levels, launch sequencing: all of these are CEO decisions made in the planning phase. Once the launch is underway, the CEO holds the CCO accountable for execution and receives regular performance updates, but does not step into operational decision-making.
If execution is going badly during a launch, the CEO’s response is to make a leadership decision (hold the CCO accountable, adjust commercial leadership, make a strategic pivot) rather than an operational one (attend launch readiness calls, review field performance data).
That distinction, maintained consistently, is what separates a CEO from a commercial operator. The investment in a clear delegation system is what makes it possible.
Related Reading
For further context, explore Delegation System for Automotive CEO: Compliance Team and Delegation System for Automotive CEO: Engineering Teams.